Phase 4 Study Dives into Real-World MS Outcomes with Teriflunomide
SEPTEMBER 15, 2016
Teriflunomide is indicated for relapsing-remitting MS once per day. In addition to efficacy and safety profiles, the study set out to uncover quality of life outcomes.
The cohort consisted of 1,000 patients – of which, 594 switches from another disease-modifying therapy (DMT) within the previous six months and 285 had not been on a DMT for the previous two years.
Scores were comparable at baseline and Week 48, with the median being 68.1 and 70.3, respectively. However, scores did slightly increase between the two time periods in three of the nine subscales.
- Activities of daily living: 58.9 and 62.5
- Psychological well-being: 62.5 and 68.8
- Relationships with friends: 58.3 and 66.7
Also on MD Magazine >>> More News from ECTRIMS 2016 in London